Simplified hepatitis C testing with same-day treatment for people who inject drugs in Armenia, Georgia and Tanzania
Official title: Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania (CUTTS HepC): a Non-randomised, Quasiexperimental, Prospective Comparative Trial
Run by Médecins du Monde · NCT06159504 · Data updated 2026-11-12
This project will test whether a simplified pathway that starts hepatitis C treatment the same day after a quick antibody test helps people who inject drugs in Armenia, Georgia, and Tanzania get treated and cured faster than the usual antibody-plus-RNA pathway.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3040 (estimated) |
| Sponsor | Médecins du Monde Academic / other |
| Locations | 1 site (Yerevan) |
| Status | Recruiting |
| Started | October 3, 2024 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | October 9, 2026 |
| Trial ID | NCT06159504 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who inject drugs or attend needle/syringe programs, able to consent in the local language, not currently or previously treated for hepatitis C, and meeting the study's medical eligibility criteria are the ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have a history of decompensated cirrhosis, uncontrolled significant comorbidities (for example uncontrolled HIV, renal dysfunction, active tuberculosis, or chronic hepatitis B), or cannot stop contraindicated medications are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a non-randomised, quasi-experimental prospective comparison of two simplified care pathways delivered in community and harm-reduction settings across Armenia, Georgia, and Tanzania. One arm follows a standard simplified model with a rapid antibody test followed by a confirmatory HCV RNA test before treatment, while the other arm starts treatment the same day based on an early (<5 minute) read of the rapid antibody test with RNA testing done after treatment initiation. Approximately 350 participants per arm will receive 12 weeks of oral sofosbuvir/velpatasvir and be followed to measure treatment start rates, sustained virological response (SVR12), feasibility across the care cascade, cost-effectiveness, and acceptability using qualitative interviews. Outcomes will compare treatment uptake, cure rates, concordance between early antibody reads and RNA, and the economic implications of the two approaches.
Why it matters
Potential benefit: If successful, the same-day antibody-driven pathway could lower barriers to care, speed treatment starts, reduce loss-to-follow-up, and lower program costs for people who inject drugs.
How similar studies have gone: Point-of-care HCV testing and same-day treatment models have improved uptake in some settings and early-read antibody results have been correlated with RNA positivity, but starting treatment without pre-treatment RNA confirmation is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Able and willing to provide informed consent in local language * Not currently on or previously had treatment for hepatitis C * Attending site for needle / syringe program, OR self-reports ever injecting drugs Exclusion Criteria: * Self-reported history of decompensate cirrhosis of the liver * Women who are pregnant or breast-feeding * Self-report other significant co-morbidities such as uncontrolled HIV infection, history of renal dysfunction, tuberculosis infection, or chronic hepatitis B infection * Unable / unwilling to stop any contraindicated medications / supplements
Where it's running
-
National Institute for Infectious Diseases
Yerevan, Armenia Recruiting
Study contacts
- Principal investigator: Margaret Hellard — Burnet
- Study coordinator: Bridget Draper
- Email: bridget.draper@burnet.edu.au
- Phone: +61 413 272 698
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV
This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.
-
Evaluating hepatitis C treatment during pregnancy
This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.
-
Decentralized treatment for hepatitis C in Brazil
This study is testing a new way to treat hepatitis C in Brazil using a medication called Epclusa to see if it helps more people get the care they need compared to traditional methods.
-
Helping young people who inject drugs start treatment for Hepatitis C
This study tests a new support program to help young adults who inject drugs start treatment for Hepatitis C and see if it works better than regular care.
-
Point-of-care testing program for Hepatitis C screening
This study is testing if quick Hepatitis C tests done during a single visit can help more at-risk adults get diagnosed and start treatment faster.
-
Screening for hepatitis B, hepatitis C and HIV using a dried blood spot
This project will try a simple dried blood spot test to check people who use drugs for hepatitis B, hepatitis C and HIV.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.